The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib

Overview of attention for article published in Frontiers in endocrinology, July 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 5,652 followers.

The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib https://t.co/WoA3Lav78V

03 Aug 2023

Reply Repost Favourite

RT @FrontEndocrinol: New Research: The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib:…

18 Jul 2023

Reply Repost Favourite

New Research: The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib: Background Sorafenib included in Chinese medical insurance is the earliest targeted drug for radioactive iodine… #Endocrinology #Endo ht

18 Jul 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.